According to Zacks, “Aerpio Pharmaceuticals Inc. is a biopharmaceutical company. It focuses on the development of novel therapeutics for vascular disorders with a concentration on diseases of the eye. The Company’ product candidates include AKB?9778, ARP1536 and AKB-4924 which are in clinical stage. Aerpio Pharmaceuticals Inc. is based in Cincinnati, United States. “
Separately, HC Wainwright reissued a hold rating and issued a $1.00 price target on shares of Aerpio Pharmaceuticals in a report on Friday, August 9th. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. Aerpio Pharmaceuticals has a consensus rating of Hold and an average target price of $5.00.
Aerpio Pharmaceuticals stock opened at $0.62 on Tuesday. Aerpio Pharmaceuticals has a 52 week low of $0.61 and a 52 week high of $4.25. The stock has a 50-day moving average price of $0.80 and a 200 day moving average price of $1.51.
Aerpio Pharmaceuticals (OTCMKTS:ARPO) last released its earnings results on Thursday, August 8th. The company reported ($0.12) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.16) by $0.04.
Large investors have recently made changes to their positions in the business. Alambic Investment Management L.P. acquired a new position in shares of Aerpio Pharmaceuticals during the 1st quarter worth approximately $85,000. Bank of New York Mellon Corp acquired a new position in shares of Aerpio Pharmaceuticals during the 4th quarter worth approximately $36,000. Jane Street Group LLC raised its stake in shares of Aerpio Pharmaceuticals by 216.3% during the 4th quarter. Jane Street Group LLC now owns 81,984 shares of the company’s stock worth $139,000 after buying an additional 56,065 shares during the period. Vanguard Group Inc. raised its stake in shares of Aerpio Pharmaceuticals by 9.1% during the 2nd quarter. Vanguard Group Inc. now owns 1,300,889 shares of the company’s stock worth $1,183,000 after buying an additional 108,749 shares during the period. Finally, BlackRock Inc. raised its stake in shares of Aerpio Pharmaceuticals by 78.8% during the 2nd quarter. BlackRock Inc. now owns 165,222 shares of the company’s stock worth $150,000 after buying an additional 72,796 shares during the period. 0.37% of the stock is owned by institutional investors.
About Aerpio Pharmaceuticals
Aerpio Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes proprietary therapeutics for treating ocular diseases. The company's lead product candidate is AKB-9778, a small molecule activator of the tie-2 pathway, which completed Phase 2a clinical trials for the treatment of diabetic macular edema.
Featured Story: What Are Treasury Bonds?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aerpio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerpio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.